Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data

Guofeng Chen, George Lau, Jing Chen et al.|PLoS ONE|2016

Cited by 44